Antibody opsonization

Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Retrieved on: 
Monday, January 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, CD16, DVM, Toxicity, Nature Biotechnology, Euronext Paris, AML, Doctor of Philosophy, Primate, Acute lymphoblastic leukemia, Acute myeloid leukemia, ADCC, IPHA, Safety, CD64, Natural killer cell, NK, Patient, Cancer, CD123, Antibody opsonization, IPH, B-ALL, Fine chemical, Sanofi, NCR1, Intrinsic and extrinsic properties

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123.
  • The studies were conducted by Innate and Sanofi and published in Nature Biotechnology on January 12, 2023.
  • A Phase 1/2 clinical trial by Sanofi is ongoing, evaluating IPH6101/SAR’579 (SAR443579), the first NKp46/CD16-based CD123-targeted ANKETTM NK cell engager, in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic syndrome (HR-MDS).
  • We're pleased with our productive collaboration with Innate Pharma, and data like this reinforce our confidence in proceeding to clinical evaluation of this novel NK cell engager."

Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism

Retrieved on: 
Wednesday, June 1, 2022
SD, Phases of clinical research, ADCC, View, Lymphocytopenia, Pharmacokinetics, Squamous cell carcinoma, Company, CMO, Antibody opsonization, Society, American Society of Clinical Oncology, Neoplasm, Harbor, Toxicity, ORR, Melanoma, HKEX, RCC, DLS, ASCO, CTLA4, Therapy, Multimedia, Leukopenia, 2021 Essex County Council election, Trae tha Truth, DCR, HCC, Trial of the century, Patient, Antibody, MOA, PR, H2L2, Renal cell carcinoma, Rash, Pharmaceutical industry, Medical imaging, Vaccine, Regulatory T cell, Safety, Tolerability

The Treg depleting activity of HBM4003 offers a potential for clinical efficacy in indications hitherto unaddressed by first generation CTLA4 inhibitors.

Key Points: 
  • The Treg depleting activity of HBM4003 offers a potential for clinical efficacy in indications hitherto unaddressed by first generation CTLA4 inhibitors.
  • HBM4003 is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice.
  • The Company's proprietary antibody technology platforms Harbour Micegenerate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format.
  • Integrating Harbour Mice, HBICE with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.

Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Friday, November 19, 2021
Patient, Lists of diseases, HER2, Cardiac muscle, Technology, Microglia, Brain, Capsid, Annual report, Private Securities Litigation Reform Act, Neoplasm, Pakistan Society of Neuro-Oncology, ADCC, Traffic barrier, Cerebrospinal fluid, Central nervous system, IV, Antibody opsonization, Breast, Breast cancer, COVID-19, Tropism, Goal, Annual general meeting, Nasdaq, Research, GLOBE, SNO, RNA, Macrophage, Mortality, U.S. Securities and Exchange Commission, AAV, Therapy, Library, CNS, Vaccine, Medical imaging

CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today will present preclinical data demonstrating that IV dosing of a proprietary AAV vector identified by the TRACER™️ screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth in models of HER2+ brain metastases. Dan R. Laks, Ph.D., Voyager Scientist II, will present key findings at 4:15 p.m. ET during the 26th Society for Neuro-Oncology (SNO) Annual Meeting.

Key Points: 
  • ET during the 26th Society for Neuro-Oncology (SNO) Annual Meeting.
  • While approved anti-HER2 therapies are effective for peripheral disease, they have limited ability to reach the CNS in sufficient concentrations to treat brain metastases.
  • We look forward to continued optimization of this innovative gene therapy approach as we progress toward clinical development.
  • Voyager intends to further optimize this gene therapy approach in ongoing studies progressing towards application of a human therapeutic.

ImmunoGenesis Expands R&D, Clinical and Business Development Teams and Opens Research Laboratory

Retrieved on: 
Wednesday, July 28, 2021
Management education, Master of Business Administration, Translational research, Articles, Academic disciplines, Education

ImmunoGenesis also announces the opening of a research laboratory in JLABS @ TMC to facilitate critical translational research for its drug development programs.

Key Points: 
  • ImmunoGenesis also announces the opening of a research laboratory in JLABS @ TMC to facilitate critical translational research for its drug development programs.
  • The previous experience of Dr. Annemarie Moseley and Cassandra Harrison together at other biotech innovators will galvanize our advancement of multiple clinical programs into 2022.
  • Moseley delivers more than 20 years of executive experience in biotech and will lead ImmunoGenesis' clinical programs.
  • Scott Cullison, MBA Acting Chief Business Officer.Cullison will be responsible for business development strategy and execution.